|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Tumor Heterogeneity Selective Pressure – Why We Need New Targets? |
| A. Oliver Sartor, MD |
| As part of an independent medical education initiative, Beyond Androgen Blockade to New Pathways and Novel Treatments in Metastatic Hormone-Sensitive Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, Oliver Sartor discusses tumor heterogeneity, selective pressure, and why we need new targets. |
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer
|
|
Alexander Wyatt, Ph.D.
|
| Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping.
|
|
|
|
|
|
|
|
|
|
|
|
| Treatment Landscape of mCRPC "Presentation" |
| Matthew Rettig, MD |
| At the 2024 UCSF-UCLA PSMA Conference, Matthew Rettig discusses the critical advancements and challenges in treating mCRPC, highlighting the shift towards precision oncology with FDA-approved treatments like PARP inhibitors and Lutetium PSMA therapy, tailored to genetic mutations and PSMA PET imaging findings. |
|
|
|
|
|
|
|
|
|
|
|
| Evaluating Early Changes in Circulating Tumor DNA Tumor Fraction as a Value Add to PSA in Predicting Early Progression in mCRPC |
| Christopher Sweeney, MBBS |
| Christopher Sweeney presented findings on evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction alongside PSA to predict early progression in mCRPC patients. Using the IMbassador250 trial data, they found that ctDNA detection at cycle 3, day 1 was associated with worse outcomes, providing additional risk stratification beyond PSA alone. |
|
|
|
|
|
| Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer - Beyond the Abstract |
| Varsha Tulpule, Gareth J. Morrison, Mary Falcone, David I. Quinn, Amir Goldkorn |
| The integration of liquid biopsies in the clinical management of metastatic prostate cancer offers a minimally invasive method for monitoring disease progression and treatment response in real-time. Techniques like CTC capture and cfDNA analysis provide valuable insights into disease burden, prognosis, and response to therapy. With ongoing advancements in liquid biopsy technologies and increasing clinical validation, these tools are poised to become integral in personalized treatment approaches for metastatic prostate adenocarcinoma. |
|
|
|
|
|
|
|
|
|
|
Revolutionizing Prostate Cancer Care: AI-Based PTEN Assessment of Digital Pathology Images as a Game-Changer in Predicting Metastasis - Beyond the Abstract
|
| Tamara Jamaspishvili, MD, Ph.D. |
| This study highlights the transformative potential of AI-based PTEN assessment in predicting metastasis and recurrence in prostate cancer patients post-surgery. By leveraging fully automated AI algorithms, clinicians can accurately identify patients at higher risk, even in cases classified as low-risk by conventional criteria. |
|
|
|
|
|
| New Targets, New Concepts for Metastatic Castration-Resistant Prostate Cancer |
| Johann De Bono, MD, Ph.D. |
| Johann De Bono highlights the heterogeneity of metastatic castration-resistant prostate cancer (mCRPC) and the need for stratification strategies. He discusses new therapeutic avenues targeting androgen receptor signaling, tumor-stroma interactions, and immunotherapy, emphasizing the importance of rational therapeutic combinations. |
|
|
|
|
|
| Correlation of the Rate of Metastasis-Free Survival with the Presence of Pathogenic Germline Genetic Mutations in Patients with Prostate Cancer at a Community Practice |
| Siddharth Ramanathan |
| Siddharth Ramanathan explores the correlation between pathogenic germline mutations and metastasis-free survival in prostate cancer patients treated at a community urology practice. Analyzing data from 363 patients who underwent germline genetic testing, the study found no significant relationship between the presence of germline alterations, patient age, Gleason score, and metastasis-free survival. |
|
|
|
|
|
|
|
|
|
|
|
